However, further experiments using mouse models with impaired central neural pathways, including NPY/AgRP and POMC, and employing a HTR2C agonist approved by the U.S. Food and Drug Administration for BW management (Bohula et al., 2018a,b) should be conducted to clarify the contribution of appetite control and the relationship between the central and peripheral autonomic neural pathways (Miller et al., 2021; Park et al., 2021; Nonogaki, 2022) in NAFLD pathology. This evidence concerns the gene NPY and metabolic dysfunction-associated steatotic liver disease.